Atlas Genetics Ltd today announces the appointment of Neil Butler as Chairman.
Mr Butler, who joined the Board in November 2011, has held a variety of senior operational, commercial and board roles in both established companies and early-stage medical diagnostic companies. He is the former CEO of Vivacta (2004-2010), a point-of-care diagnostics company offering ultra-high sensitivity immunoassay testing. Neil established Vivacta whilst Business Development Director of Quester Capital, who subsequently became investors. Between 1999 and 2004, Neil was CEO of Oxford Biosensors, an Oxford University spin-out offering hand-held medical diagnostics. Prior to this, he was VP, Performance Films, Rexam Inc. Most recently, he has served as a consultant to the medical devices and diagnostics industry, including projects for a number of European Venture Capital companies and BVGH, a San Francisco based organisation working with The Gates Foundation to set technical and business standards in diagnostics for the developing world. Neil is also a director of Radisens Diagnostics.
Dr John Clarkson, Chief Executive Officer of Atlas, commented: “Neil brings extensive medical diagnostic expertise to Atlas Genetics which will be invaluable as we move forward with the development and commercialisation of our assay system for the ultra-rapid point-of-care detection and diagnosis of infectious diseases, including common sexually transmitted diseases and MRSA.”